Several studies have suggested that the receptor tyrosine kinase (RTK) family, including EGFR, HER2, HER3, and HER4, is one of the major drug resistance mechanisms against pharmacological therapeutic reagents in different cancers, including NSCLC [17,18,19]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.